

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain [Corrigendum]

Thanawala S, Shah R, Somepalli V, Alluri KV, Desomayanandam P, Bhuvanendran A. *Clin Pharmacol.* 2021;13:91–100.

The authors have informed the journal that on page 93, Table 2 “Efficacy Endpoints”, for the primary endpoint “Visual analogue scale after 80-m fast-paced walk test”, the parameter “Change from B to D45” is erroneously mentioned as -1.5 ± 0.4 where it should be -1.0 ± 0.4 .

The correct Table 2 is:

On page 96, Table 3 “Biochemical and Inflammatory Markers”, for C-reactive protein, the unit is erroneously mentioned as (mg/dL), where it should be (mg/L).

The correct Table 3 is:

The authors advise these errors/corrections will not affect the previously shown results/conclusions and apologize for any confusion this may have caused.

Table 2 Efficacy Endpoints

	WDTE60N (n = 49)		Placebo (n = 47)		p-value
	Mean \pm SD	Median (IQR)	Mean \pm SD	Median (IQR)	
Visual analogue scale after 80-m fast-paced walk test					
Baseline	5.4 \pm 0.9	5 (5, 6)	5.4 \pm 0.8	5 (5, 6)	
Day 45	4.4 \pm 0.8	4 (4, 5)	4.9 \pm 0.6	5 (5, 5)	
Day 90	3.8 \pm 0.8	4 (3, 4)	4.8 \pm 0.6	5 (4.3, 5)	
Change from B to D45	-1.0 \pm 0.4	-1 (-1, -1)	-0.4 \pm 0.6	0 (-1, 0)	< 0.0001*
Change from B to D90	-1.5 \pm 0.7	-2 (-2, -1)	-0.6 \pm 0.8	0 (-1, 0)	< 0.0001*
80 m- fast-paced walk test (s)					
Baseline	70.3 \pm 23.9	60.1 (59.1, 60.5)	69.2 \pm 23.4	60.08 (57.7, 60.3)	
Day 45	65.2 \pm 18.8	60.0 (58.9, 60.1)	62.9 \pm 15.2	60.04 (57.8, 60.2)	
Day 90	59.3 \pm 9.5	59.8 (57.3, 60.1)	62.4 \pm 15.4	60.0 (57.4, 60.1)	
Change from B to D45	-5.0 \pm 16.5	-0.09 (-0.3, -0.04)	-6.3 \pm 18.6	0.0 (-0.07, 0.07)	0.0002*
Change from B to D90	-11.0 \pm 26.1	-0.2 (-2, -0.06)	-6.8 \pm 23.3	0 (-0.2, 0.2)	0.0011*
9-step stair climb test (s)					
Baseline	49.2 \pm 40.9	60.2 (10.8, 60.5)	44.8 \pm 39.2	60.2 (10.6, 60.5)	
Day 45	40.2 \pm 29.7	60.0 (10.6, 60.2)	39.9 \pm 32.1	60.1 (10.8, 60.2)	
Day 90	36.9 \pm 24.3	52.0 (10.5, 60.1)	37.0 \pm 27.6	52 (10.8, 60.1)	
Change from B to D45	-8.9 \pm 21.0	-0.1 (-0.4, -0.07)	-4.9 \pm 21.0	0.04 (-0.07, 0.09)	< 0.0001*
Change from B to D90	-12.3 \pm 24.2	0.2 (-0.8, -0.1)	-7.8 \pm 24.2	0.04 (-0.2, 0.1)	< 0.0001*

(Continued)

Table 2 (Continued).

	WDTE60N (n = 49)		Placebo (n = 47)		p-value
	Mean ± SD	Median (IQR)	Mean ± SD	Median (IQR)	
Primary knee flexion (degree)					
Baseline	134.2 ± 0.9	134 (134, 135)	134.4 ± 0.9	134 (134, 135)	0.3657
Day 45	134.1 ± 0.6	134 (134, 134)	134.3 ± 0.8	134 (134, 135)	
Day 90	134.0 ± 0.6	134 (134, 134)	134.3 ± 0.7	134 (134, 134)	
Change from B to D45	-0.1 ± 0.7	0 (0, 0)	-0.0 ± 0.5	0 (0, 0)	
Change from B to D90	-0.2 ± 0.6	0 (0, 0)	-0.1 ± 0.8	0 (0, 0)	

Note: *p-value less than 0.05 ($p \leq 0.05$) is statistically significant.

Abbreviations: B to D, baseline to day; IQR, interquartile range.

Table 3 Biochemical and Inflammatory Markers

	WDTE60N (n = 49)		Placebo (n = 47)		p-value*
	Mean ± SD	Median (IQR)	Mean ± SD	Median (IQR)	
C-reactive protein (mg/L)					
Baseline	5.3 ± 14.0	1.7 (0.9, 4.8)	3.0 ± 3.6	1.6 (0.8, 3.4)	0.2868
Day 90	2.6 ± 2.6	1.6 (0.9, 3.4)	9.5 ± 26.8	1.9 (1, 4)	
Change from B to D90	-2.7 ± 14.5	-0.2 (-1.5, 1.1)	6.5 ± 26.7	0.0 (-0.8, 1.4)	
p-value**	0.2327		0.2676		
Interleukin 6 (pg/mL)					
Baseline	21.1 ± 31.3	8.1 (0.07, 29.7)	20.5 ± 36.3	3.3 (0.07, 18.4)	0.1699
Day 90	30.5 ± 52.6	4.1 (0.7, 26.7)	26.8 ± 40.2	8.3 (1, 31.7)	
Change from B to D90	9.4 ± 62.7	0.5 (-19, 12.8)	6.3 ± 36.6	3.1 (-0.79, 22.6)	
p-value**	0.4641		0.0188		
Tumor necrosis factor- α (pg/mL)					
Baseline	30.4 ± 52.5	2.6 (0.2, 48.8)	31.6 ± 60.6	0.7 (0.1, 34.4)	0.0927
Day 90	14.9 ± 45.1	0.7 (0.7, 0.7)	22.4 ± 32.6	0.7 (0.7, 30.7)	
Change from B to D90	-15.5 ± 67.1	-0.2 (-24.9, 0.6)	-9.3 ± 67.3	0.5 (-20.6, 12.4)	
p-value**	0.0054		0.4522		
Matrix metalloproteinase-3 (ng/mL)					
Baseline	20.9 ± 15.4	19.7 (6.6, 35.0)	18.9 ± 16.6	12.5 (5.5, 34.2)	0.1387
Day 90	14.1 ± 9.4	12.5 (6.6, 19.6)	15.9 ± 9.7	13 (7.7, 23.5)	
Change from B to D90	-6.8 ± 14.9	-7 (-15.7, 2.5)	-3.0 ± 14	-0.4 (-9.4, 5.7)	
p-value**	0.0017		0.1335		

Notes: *p-value from the Mann-Whitney U-test comparing the difference between placebo versus WDTE60N; **p-value from Wilcoxon signed-rank test comparing levels at baseline to day 90.

Abbreviations: B to D, baseline to day; IQR, interquartile range.

Clinical Pharmacology: Advances and Applications

Dovepress

Publish your work in this journal

Clinical Pharmacology: Advances and Applications is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of drug experience in humans. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-pharmacology-advances-and-applications-journal>